SOGUG
@sogug1
Cuenta oficial del Grupo Español de Oncología Genitourinaria / Spanish Oncology Genitourinary Group's official account
ID:1136854537
http://www.sogug.es 31-01-2013 12:21:54
7,2K Tweets
2,6K Followers
828 Following
🧪 #Laboratorios | Cada año se diagnostican en España más de 22.000 nuevos casos de cáncer de vejiga, un tumor históricamente más frecuente en hombres que cada vez afecta más a las mujeres
SOGUG Roche España Verónica Calderero Hospital Clínic Begoña Mellado
i.mtr.cool/ldgmgrdtjt
Proyecto 50:50 en Pamplona.
📅 Martes 4 de junio a partir de las 18,30 horas
En el Colegio Oficial de Médicos.
nuria lainez, Dra. María José Lecumberri, Jose Luis Perez-Gracia
Con la colaboración de Asociación Española Contra el Cáncer Navarra ALCER Navarra
Pacientes, familiares e interesad@, os esperamos!!!
SOGUG sala llena desde primera hora en la I reunión multidisciplinar de cáncer de vejiga SOGUG enhorabuena Arancha Glez del Alba Bego PValderrama
Association between enfortumab-vedotin related cutaneous reaction and serum albumin levels in patients with advanced #UrothelialCancer . Presentation by Hayato Yamamoto, MD. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3JLMAEj
Tumor size reduction (≥10% ) resulting from pre-surgical systemic therapy predicts improved survival following cytoreductive nephrectomy. Presentation by Daniel Shapiro UW Urology. #AUA24 written coverage by Julian Chavarriaga > bit.ly/4drNDXp
We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer.
With a huge contribution of our multinational team we uncovered
Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…
Great to be in Sitges! KN564 expectations for subsequent therapy numbers in adjuvant #kidneycancer pembrolizumab should be tempered because it is a moving target in how we capture it Tom Powles #IKCS2024 . So I think KN564 post therapy numbers are reasonable.
How to treat metastatic RCC and Urothelial carcinoma after progression on adjuvant IO ? Based upon available data. Very good slide for clinical decisions by Ursula Vogl ESMO - Eur. Oncology .